Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold

Zurlo, Matteo; Romagnoli, Romeo; Oliva, Paola; Gasparello, Jessica; Finotti, Alessia; Gambari, Roberto

doi:10.3390/ijms23115991

Cited by 9 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Singh et al, miR-155 mitigates angiotensin II receptor type-1-mediated angiogenesis to suppress GBM growth [ 81 ]. Zurlo et al suggested the combined use of an anti-miR-10b-5p and a 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-1 H -imidazole derivative as potential strategy against GBM to improve the efficacy of antitumor therapy and reduce side effects at the same time [ 82 ]. He et al concluded that miR-210-3p can inhibit glioma growth, migration, and proliferation by targeting the iron–sulfur cluster assembly protein (Iscu) gene in mouse models [ 83 ].…”

Section: Microrna-based Therapeutics Against Glioblastomamentioning

confidence: 99%

Systems Medicine for Precise Targeting of Glioblastoma

Zeng¹,

Zeng

2023

Mol Biotechnol

View full text Add to dashboard Cite

Glioblastoma (GBM) is a malignant cancer that is fatal even after standard therapy and the effects of current available therapeutics are not promising due its complex and evolving epigenetic and genetic profile. The mysteries that lead to GBM intratumoral heterogeneity and subtype transitions are not entirely clear. Systems medicine is an approach to view the patient in a whole picture integrating systems biology and synthetic biology along with computational techniques. Since the GBM oncogenesis involves genetic mutations, various therapies including gene therapeutics based on CRISPR-Cas technique, MicroRNAs, and implanted synthetic cells endowed with synthetic circuits against GBM with neural stem cells and mesenchymal stem cells acting as potential vehicles carrying therapeutics via the intranasal route, avoiding the risks of invasive methods in order to reach the GBM cells in the brain are discussed and proposed in this review. Systems medicine approach is a rather novel strategy, and since the GBM of a patient is complex and unique, thus to devise an individualized treatment strategy to tailor personalized multimodal treatments for the individual patient taking into account the phenotype of the GBM, the unique body health profile of the patient and individual responses according to the systems medicine concept might show potential to achieve optimum effects.

show abstract

Section: Microrna-based Therapeutics Against Glioblastomamentioning

confidence: 99%

Systems Medicine for Precise Targeting of Glioblastoma

Zeng¹,

Zeng

2023

Mol Biotechnol

View full text Add to dashboard Cite

show abstract

“…An interesting approach that employs combined treatment has been recently proposed by our group, associating compounds interfering with tubulin polymerization and specific antimiRNA molecules targeting upregulated oncomiRNAs (such as miR-221-3p or miR-10b-5p). Combined treatment appears to have synergistic effects on the activation of apoptosis and cell-cycle alterations, demonstrating that this therapeutical strategy can increase the efficacy of anticancer treatments [ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Cells in the early stage of the apoptotic process (represented in lower right quadrants in the plots) were stained with the Annexin V-PE conjugated; cells in the late phase of apoptosis (upper right quadrants) were stained with Annexin V-PE plus 7-AAD; the necrotic cells were stained only by 7-AAD (upper left quadrants) while live cells showed no staining (lower left quadrants). Following that, samples were obtained using a Guava ® Muse ® Cell Analyzer (Luminex Corporation, Austin, TX, USA), and data was analyzed using the Luminex Annexin V and Dead Cell Software Module (as previously reported [ 8 ]).…”

Section: Methodsmentioning

confidence: 99%

“…Concerning combined therapeutic approaches, we have recently demonstrated and reported that antitumor derivatives can be combined with molecules targeting specific microRNAs [ 6 , 7 , 8 , 9 ], short noncoding RNAs that can operate as gene regulators by directly inhibiting translation or triggering the cleavage of target mRNA transcripts [ 10 , 11 , 12 ]. MiRNAs may play a role in the pathogenesis of cancer, according to well-established and acknowledged data [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined Treatment of Cancer Cells Using Allyl Palladium Complexes Bearing Purine-Based NHC Ligands and Molecules Targeting MicroRNAs miR-221-3p and miR-222-3p: Synergistic Effects on Apoptosis

et al. 2023

Self Cite

View full text Add to dashboard Cite

Combined treatments employing lower concentrations of different drugs are used and studied to develop new and more effective anticancer therapeutic approaches. The combination therapy could be of great interest in the controlling of cancer. Regarding this, our research group has recently shown that peptide nucleic acids (PNAs) that target miR-221 are very effective and functional in inducing apoptosis of many tumor cells, including glioblastoma and colon cancer cells. Moreover, in a recent paper, we described a series of new palladium allyl complexes showing a strong antiproliferative activity on different tumor cell lines. The present study was aimed to analyze and validate the biological effects of the most active compounds tested, in combination with antagomiRNA molecules targeting two miRNAs, miR-221-3p and miR-222-3p. The obtained results show that a “combination therapy”, produced by combining the antagomiRNAs targeting miR-221-3p, miR-222-3p and the palladium allyl complex 4d, is very effective in inducing apoptosis, supporting the concept that the combination treatment of cancer cells with antagomiRNAs targeting a specific upregulated oncomiRNAs (in this study miR-221-3p and miR-222-3p) and metal-based compounds represents a promising therapeutic strategy to increase the efficacy of the antitumor protocol, reducing side effects at the same time.

show abstract

“…n. MCH100105) at room temperature and protected from light for 20 min. The samples were then analyzed using Guava ® Muse ® Cell Analyzer and data were acquired by utilizing Annexin V and Dead Cell Software Module (Luminex Corp., Austin, TX, USA), as previously reported [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

Production and Characterization of K562 Cellular Clones Hyper-Expressing the Gene Encoding α-Globin: Preliminary Analysis of Biomarkers Associated with Autophagy

Zurlo

Gasparello

Cosenza

et al. 2023

Genes

Self Cite

View full text Add to dashboard Cite

One of the most relevant pathophysiological hallmarks of β-thalassemia is the accumulation of toxic α-globin chains inside erythroid cells, which is responsible for their premature death (hemolysis). In this context, the availability of an experimental model system mimicking the excess in α-globin chain production is still lacking. The objective of the present study was to produce and characterize K562 cellular clones forced to produce high amounts of α-globin, in order to develop an experimental model system suitable for studies aimed at the reduction of the accumulation of toxic α-globin aggregates. In the present study, we produced and characterized K562 cellular clones that, unlike the original K562 cell line, stably produced high levels of α-globin protein. As expected, the obtained clones had a tendency to undergo apoptosis that was proportional to the accumulation of α-globin, confirming the pivotal role of α-globin accumulation in damaging erythroid cells. Interestingly, the obtained clones seemed to trigger autophagy spontaneously, probably to overcome the accumulation/toxicity of the α-globin. We propose this new model system for the screening of pharmacological agents able to activate the full program of autophagy to reduce α-globin accumulation, but the model may be also suitable for new therapeutical approaches targeted at the reduction of the expression of the α-globin gene.

show abstract

Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold

Cited by 9 publications

References 61 publications

Systems Medicine for Precise Targeting of Glioblastoma

Systems Medicine for Precise Targeting of Glioblastoma

Combined Treatment of Cancer Cells Using Allyl Palladium Complexes Bearing Purine-Based NHC Ligands and Molecules Targeting MicroRNAs miR-221-3p and miR-222-3p: Synergistic Effects on Apoptosis

Production and Characterization of K562 Cellular Clones Hyper-Expressing the Gene Encoding α-Globin: Preliminary Analysis of Biomarkers Associated with Autophagy

Contact Info

Product

Resources

About